BenzingaAugust 13, 2026 at 7:21 AM NY22 days ago
Cullinan Therapeutics Zipalertinib Combo Clears Key Phase 3 Hurdle As First-Line Lung Cancer Treatment Option Takes Shape
Cullinan Therapeutics and Taiho report positive Phase 3 trial results for zipalertinib in treating advanced lung cancer.
Read the Full Story at the Source
The summary here comes from the news provider; the rest of the article lives on the publisher's site — Benzinga
Companies in This Story
Related Stories
The trading volume of these stocks is deviating from the norm in today's session.
ChartMill1 hour ago
Discover which S&P500 stocks are making waves on Friday.
ChartMill1 hour ago
Sodexo : Monthly disclosure on share capital and voting rights August 31, 2026
Yahoo2 hours ago
ANF vs. TPR: Which Stock Is the Better Value Option?
Yahoo2 hours ago
Anthropic's IPO Push Just Got a $15 Billion Backstop
Yahoo2 hours ago